TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03490812

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET scan
Description: Investigational PET scan as add-on to standard-of-care scan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Retrospective data analysis
Description: Review of pre-existing data from January 1, 2001 through December 5, 2017
Study: NCT04091607

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music Therapy
Description: Subject will listen to Music using provided ear buds or headphones.
Study: NCT02529228

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal (Eating) Frequency
Description: Dividing meal intake into 2 or 6 meals with equal energy content

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal (Eating) Frequency
Description: Dividing meal intake into 2 or 6 meals with equal energy content

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal (Eating) Frequency
Description: Dividing meal intake into 2 or 6 meals with equal energy content

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal (Eating) Frequency
Description: Dividing meal intake into 2 or 6 meals with equal energy content

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein Composition
Description: Consuming meals with higher or lower protein.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein Composition
Description: Consuming meals with higher or lower protein.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein Composition
Description: Consuming meals with higher or lower protein.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein Composition
Description: Consuming meals with higher or lower protein.
Study: NCT01838980

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Motus GI Clean-Up Device
Study: NCT02471326

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVMAB060-00-AB (VRC01)
Description: A potent HIV-specific monoclonal antibody
Study: NCT03300596

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief intervention to prevent suicide attempt
Description: A patient-centered, 3-session intervention that calls for videotaping the narrative story of a patient's suicide attempt, in his/her own words (session 1); reviewing segments of the tape to arrive at a shared understanding of the attempt and the sequence of events that led to it (session 2); and using this information, along with a homework task completed by the patient in-between sessions, in order to develop a collaborative, comprehensive written safety plan that addresses the patient's unique vulnerabilities (session 3).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Enhanced treatment as usual
Description: Safety procedures' control intervention. For these procedures we will share summary results of the research assessments regarding suicidal thoughts, suicidal behaviors, alcohol and drug use and related problems, and depressive symptoms with appropriate hospital clinical staff. We will also arrange to send this information, with participants' permission, to their ongoing therapist or treatment program and, if none exists, to the therapist or program to which they are being referred. In this regard, the research assessment protocol serves a dual function of helping with additional monitoring of high-risk patients in addition to providing data for the study.
Study: NCT01864005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: 90mg tablets. loading dose of 180mg ticagrelor tablets (two 90mg tablets) taken orally, followed by 90mg of ticagrelor 12 hours after the first dose. Duration of treatment: 6 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 75mg capsule. loading dose of 600mg clopidogrel capsules (eight 75mg capsules) taken orally, follow by 75mg of clopidogrel capsules orally od. Duration of treatment: 6 weeks.
Study: NCT03764293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: Subjects receive SHR-1210 intravenously, Dosage form: lyophilised powder, Strength: 200 mg /vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Subjects receive Apatinib orally, Dosage form: tablet, Strength: 250 mg/tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Subjects receive Sorafenib orally, Dosage form: tablet, Strength: 0.2 g/tablet
Study: NCT04421690

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivia Training
Description: Participants (n=15) will receive computerized trivia questions to answer and submit 3 times/week for 8 weeks.
Study: NCT03962985

Intervention type: OTHER
Group type: OTHER
Intervention: Guided tour at the Montreal Museum of Fine Arts
Description: * The duration of the participation -3 months~* The duration of the guided tour-45 minutes, each week~* All participants will be asked to fill out some specific online questionnaires during their participations in the study
Study: NCT03682497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977
Description: AZD9977 capsules taken orally for 28 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: Spironolactone tablets taken orally for 28 days.
Study: NCT04004598

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: golf training
Description: 12 weeks of training by Professional Golf Association professional
Study: NCT00574574

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: anthocyanin
Description: 500mg/d of anthocyanin each day for 12 weeks (84days). Route of administration: oral capsules, 4 X 250mg capsules (125mg anthocyanin/ capsule). Dosage advice; 2 capsules to be taken with food, twice per day (n=4 in total).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: anthocyanin
Description: 500mg/d of anthocyanin each day for 12 weeks (84days). Route of administration: oral capsules, 4 X 250mg capsules (125mg anthocyanin/ capsule). Dosage advice; 2 capsules to be taken with food, twice per day (n=4 in total).
Study: NCT02059083

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart rate variability biofeedback

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT
Study: NCT05164445

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Transbronchial forceps biopsy
Description: All patients with peripheral lung lesion suspected of lung cancer detected on the chest computed tomography (CT) and mini probe endobronchial ultrasound (RP-EBUS) scans were enrolled. Transbronchial forceps biopsy (TBFB) was performed for all these patients.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Transbronchial forceps biopsy+Transbronchial cryobiopsy
Description: All patients with peripheral lung lesion suspected of lung cancer detected on the chest computed tomography (CT) and RP-EBUS scans were enrolled. TBFB was performed for all these patients. In addition, all of these patients, with no contraindications, underwent transbronchial cryobiopsy (TBCB)
Study: NCT01227902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retigabine IR
Description: Flexible dose between 300 mg/day (minimum) and 1200 mg/day (maximum).
Study: NCT04264624

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Perioflow and Erythritol powder and ultrasonic debridement
Description: Airflow and Perioflow combined with Erythritol powder will be used as an adjunct therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airflow and Erythritol powder and ultrasonic debridement
Description: Airflow combined with Erythritol powder will be used as an adjunct therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Airflow and Erythritol powder and ultrasonic debridement
Description: Airflow combined with Erythritol powder will be used as an adjunct therapy
Study: NCT04655651

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention for both groups.

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention for both groups.
Study: NCT04704947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nonselective beta blocker
Description: nonselective beta blocker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cardio-selective beta blocker group
Description: cardio-selective beta blocker group

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: alendronate sodium
Description: alendronate sodium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alendronate sodium
Description: alendronate sodium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alendronate sodium
Description: alendronate sodium
Study: NCT00244140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iopromide 370 mg I/mL
Description: Iopromide (Ultravist 370 mg I/mL) administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iopromide 300 mg I/mL
Description: Iopromide (Ultravist 300 mg I/mL) administered intravenously
Study: NCT02884505

Intervention type: DEVICE
Intervention: Pupillometry
Description: Measures pupillary dynamics in darkness and light conditions

Intervention type: BEHAVIORAL
Intervention: Psychomotor Vigilance Task
Description: Response time task measuring neurobehavioral alertness

Intervention type: OTHER
Intervention: Auditory Evoked Potential
Description: Measure of electroencephalographic response to standardized auditory tones

Intervention type: BEHAVIORAL
Intervention: Hypersomnia Severity Index
Description: Self-report measure of hypersomnolence
Study: NCT01688531

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CD0271 0.1%/CD1579 2.5% gel
Description: one application (pea-sized amount according to the labelling) on a half-face, 5 to 7 days for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD0271 0.1%/CD1579 2.5% gel vehicle
Description: one application (pea-sized amount according to the labelling) on a half-face, 5 to 7 days for 6 months
Study: NCT03208582

Intervention type: DRUG
Group type: OTHER
Intervention: Risedronate Sodium
Description: Participants will be initially tested on the response to mechanical stimulation as a baseline and then tested again after 6 weeks treatment with Risedronate

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Calcichew tablets
Description: Participants will take calcichew tablets during the 6 week period of risedronate treatment
Study: NCT03554486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fiasp
Description: Fiasp insulin will be used for 2 weeks with the 670G hybrid closed-loop system

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fiasp
Description: Fiasp insulin will be used for 2 weeks with the 670G hybrid closed-loop system

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Novolog
Description: Novolog insulin will be used for 2 weeks with the 670G hybrid closed-loop system

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Novolog
Description: Novolog insulin will be used for 2 weeks with the 670G hybrid closed-loop system
Study: NCT02215811

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cells
Study: NCT03555019

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Formulaid
Description: Supplementation with ARA and DHA

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MCT-oil
Description: Supplementation with medium chain fatty acids
Study: NCT02084290

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shared Decision Making Program
Description: This study is cluster randomized by study-site, Subjects enrolled at intervention sites will access an educational program and risk prediction tool. Their decisions about treatments will be compared to subjects that did not view the educational program or risk prediction tool.
Study: NCT02571335

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Training
Description: Week 1: Ratio of continuous and interval training of 2:1. Entry point at day one with 20 min of continuous, physiologically defined heart rate controlled cycling at 50-60 rounds per minutes at 75% of HRpeak.~Resistance training is performed with 70% of the subjective-felt 1-round maximum with three sets and 10-12 repetitions and three exercises for the upper and lower extremities.~Week 2 Progression of endurance training: 4x5 minutes with 2 Minutes between each interval performed at 80% of HRmax Progression resistance training: 75% of the subjective-felt 1-round maximum with three sets and 8-10 repetitions and three exercises for the upper and lower extremities.~Week 3 Same as week 2.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Normal Training
Description: The control intervention is the normal rehabilitation program of the Valens clinic.
Study: NCT04176848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CFI-400945
Description: CFI-400945 32 mg: Cycle 1: Days 1-7, then Days 15-21; Cycle 2 on: orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Cycle 2 on: Durvalumab 1500mg IV on Day 1 (28 day cycles)
Study: NCT01280877

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tACS
Description: Transorbital alternating current stimulation (tACS) is applied with a multi-channel device with paraorbital montage of 4 stimulation electrodes generating weak current pulses in predetermined firing bursts of 8 to 14 pulses. The amplitude of each current pulse was below 1000 microA. Current intensity was individually adjusted according to how well patients perceived phosphenes, i.e. any sensation of flickering light in response to the rtACS stimulation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: tACS is applied with the same device with equal electrodes set-up procedures but only one of four channels actually delivers current. The current intensity of this channel is individually adjusted (preselected on the side of lesioned eye) according with patient able to clearly perceive single phosphenes or any skin irritation phenomena (like weak sense of needles or vibration) whenever a single pulse is applied. The amplitude of pulses is always below 1000 microA. Current pulses are given as 1 pulse per minute during 25-35 min of session time. Session duration is equal for verum and sham patients. The perception of the single pulses leaves sham patients at the impression that they might receive the verum intervention, but total number of pulses is less than 0,5% of verum tACS.
Study: NCT01739062

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic risk assessment
Study: NCT00441116

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dutasteride 0.5mg oral tablets
Description: Dutasteride
Study: NCT03803319

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fibre 1 (combined fibres)
Description: Dietary fibre supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fibre 2 (natural fibres)
Description: Dietary fibre supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary Supplement: placebo
Description: Dietary supplement
Study: NCT02751385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microgynon

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Study: NCT00862641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson
Description: IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV
Study: NCT04128813

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vertical whole body vibration
Description: A neuromuscular treatment using two types of whole body vibration platforms, a rotational and a vertical platform.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vertical whole body vibration
Description: A neuromuscular treatment using two types of whole body vibration platforms, a rotational and a vertical platform.
Study: NCT03945617

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Treatment Protocol
Description: The Unified Treatment Protocol (UP) is a transdiagnostic psychotherapeutic treatment manual for emotional disorders, that is based on CBT principles and focuses on changing dysfunctional emotion regulation.
Study: NCT03179605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFD06
Description: Apply twice per day for 15 days
Study: NCT00888043

Intervention type: DRUG
Group type: OTHER
Intervention: CNTO 95 and avastin
Description: STAGE 1 (Dose escalation) Cohort # subjects CNTO 95 Bevacizumab~* 2 3-6 2.5 mg/kg IV Q3 weeks 7.5 mg/kg IV Q3 weeks~* 1 3-6 2.5 mg/kg IV Q3 weeks 15 mg/kg IV Q3 weeks~  1. 3-6 5 mg/kg IV Q3weeks 15 mg/kg IV Q3 weeks~ 2. 3-6 10 mg/kg IV Q3 weeks 15 mg/kg IV Q3 weeks STAGE 2 (Biomarker) Cohort # subjects CNTO 95 Bevacizumab~ 3. 20 Recommended Phase II Dose Recommended Phase II Dose
Study: NCT01419197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine
Description: The dose was calculated based on the patient's Baseline weight on Day 1 of each 3-week treatment cycle. The same dose was administered in subsequent cycles if the patient's weight stayed within 10% of the Baseline weight. If there was a weight change \> 10%, the dose was adjusted accordingly and the recorded weight became the new Baseline weight. Trastuzumab emtansine was provided as a single-use lyophilized formulation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment of physician's choice
Description: The treatment of physician's choice (TPC) was a protocol-specified approved or standard of care therapy or combination of therapies, based on frequently used regimens for late-line HER2-positive metastatic breast cancer treatment after receipt of both trastuzumab- and lapatinib-containing regimens. The therapies included single-agent chemotherapy, single-agent (e.g., tamoxifen or aromatase inhibitor) or dual-agent (e.g., aromatase inhibitor with luteinizing hormone releasing hormone \[LHRH\] agonist) hormonal therapy for hormone receptor positive-disease, and HER2-directed therapy.~Participants who had documented progressive disease (PD) were eligible to switch treatment to receive trastuzumab emtansine 3.6 mg/kg. Participants who switched treatment remained on trastuzumab emtansine treatment until another PD event or unmanageable toxicity.~The formulation, storage, and preparation of all TPC were as per the appropriate package insert or national prescribing information.
Study: NCT01658306

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: remote ischemic preconditioning
Description: RIPC consists of five 5-min cycles of right upper arm ischemia/reperfusion, induced by an automated cuff-inflator placed on the right upper arm which is inflated to 200 mmHg for 5mins followed by deflating the cuff for 5mins, each patient in the RIPC group will have the treatment twice a day for two weeks.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham remote ischemic preconditioning
Description: Sham RIPC consists of five 5-min cycles of right upper arm ischemia/reperfusion, induced by an automated cuff-inflator placed on the right upper arm which is inflated to 50 mmHg for 5mins followed by deflating the cuff for 5mins, each patient in the placebo RIPC group will have the treatment twice a day for two weeks.
Study: NCT02366884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Bacterial Agents
Description: Doxycycline, Paramomycin, Clarithromycin, Clindamycin, Dapsone, Miltefosine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Bacterial Agents
Description: Doxycycline, Paramomycin, Clarithromycin, Clindamycin, Dapsone, Miltefosine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Fungal Agents
Description: Itraconazole, Amphotericin B liposomal, Fluconazole, Terbinafine, Voriconazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Fungal Agents
Description: Itraconazole, Amphotericin B liposomal, Fluconazole, Terbinafine, Voriconazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Protozoal Agents
Description: Nitazoxanide, Chloroquine, Albendazole, Ivermectin, Mebendazole, Metronidazole, Praziquantel, Levamisole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Protozoal Agents
Description: Nitazoxanide, Chloroquine, Albendazole, Ivermectin, Mebendazole, Metronidazole, Praziquantel, Levamisole
Study: NCT00636363

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bausch & Lomb Multipurpose Solution - Rub Care
Description: Daily care for contact lenses - rub care regimen

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bausch & Lomb Multipurpose Solution - No Rub Care
Description: Daily care for contact lenses - no rub care regimen

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ciba Vision Aquify Multipurpose Solution
Description: daily care for contact lenses
Study: NCT03368690

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oligopin®
Description: At the treatment period (0th to 4th week of the experiment), subjects with ADHD will receive 1\~3 capsules of polyphenolic extract from pine bark (25mg or 50 mg Oligopin per capsule) according to their body weight and age. The 5th to 6th week will be the washout period. The control group and Oligopin group will be cross-over at 7th week to 10th week of the experiment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: At the treatment period (0th to 4th week of the experiment), subjects with ADHD will receive 1\~3 capsules of polyphenolic extract from pine bark (25mg or 50 mg Oligopin per capsule) according to their body weight and age. The 5th to 6th week will be the washout period. The control group and Oligopin group will be cross-over at 7th week to 10th week of the experiment.
Study: NCT02316405

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm and Leg Cycling Exercise for Walking after Stroke
Study: NCT01473797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Subcutaneous injections, 0,1 mg/kg/day for 5 days, one course per month for 4 months
Study: NCT02068547

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: locally harvested autograft, demineralized bone matrix, and cadaveric allograft

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspirate